Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach

Journal of Affective Disorders

Volumn 156, Issue , 2014, Pages 1-7

  McIntyre, Roger S ^a,b,c   Filteau, Marie Josée ^d,e   Martin, Lawrence ^f   Patry, Simon ^d,g   Carvalho, Andre ^b,h   Cha, Danielle S ^a,b   Barakat, Maxime ⁱ   Miguelez, Maia ⁱ  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e Clinique Marie Fitzbach   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

ⁱ Bristol Myers Squibb Canada   (Canada)

Author keywords

Atypical antipsychotics; Augmentation; Combination; Lithium; Major depressive disorder; Treatment resistant depression (TRD)

Indexed keywords

ATYPICAL ANTIPSYCHOTICS; AUGMENTATION; COMBINATION; LITHIUM; MAJOR DEPRESSIVE DISORDER; TREATMENT-RESISTANT DEPRESSION (TRD);

ADULT; ALGORITHMS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS;

EID: 84895065146     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.10.043     Document Type: Review

References (44)

1. S.H. Abbasi, F. Hosseini, A. Modabbernia, M. Ashrafi, and S. Akhondzadeh Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study J. Affect. Disord. 141 2-3 2012 308 314
2. P. Blier, H.E. Ward, P. Tremblay, L. Laberge, C. Hebert, and R. Bergeron Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study Am. J. Psychiatr. 167 3 2010 281 288
3. P.J. Carlson, N. Diazgranados, A.C. Nugent, L. Ibrahim, D.A. Luckenbaugh, and N. Brutsche et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study Biol. Psychiatr. 73 12 2013 1213 1221
4. D.S. Cha, and R.S. McIntyre Treatment-emergent adverse events associated with atypical antipsychotics Expert Opin. Pharmacother. 13 11 2012 1587 1598
5. N. Diazgranados, L.A. Ibrahim, N.E. Brutsche, R. Ameli, I.D. Henter, and D.A. Luckenbaugh et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder J. Clin. Psychiatr. 71 12 2010 1605 1611
6. C. DeBattista, K. Doghramji, M.A. Menza, M.H. Rosenthal, and R.R. Fieve Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study J. Clin. Psychiatr. 64 9 2003 1057 1064 (Pubitemid 37158251)
7. B.W. Dunlop, P. Crits-Christoph, D.L. Evans, J. Hirschowitz, H.B. Solvason, and K. Rickels et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study J. Clin. Psychopharmacol. 27 6 2007 614 619 (Pubitemid 351339449)
8. M. Fava, M.E. Thase, and C. DeBattista A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness J. Clin. Psychiatr. 66 1 2005 85 93
9. M. Fava, D. Mischoulon, D. Iosifescu, J. Witte, M. Pencina, and M. Flynn et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study) Psychother. Psychosom. 81 2 2012 87 97
10. P.J. Gallagher, V. Castro, M. Fava, J.B. Weilburg, S.N. Murphy, and V.S. Gainer et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study Am. J. Psychiatr. 169 10 2012 1065 1072
11. P.E. Greenberg, R.C. Kessler, H.G. Birnbaum, S.A. Leong, S.W. Lowe, and P.A. Berglund et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatr. 64 12 2003 1465 1475 (Pubitemid 41270106)
12. L. Ibrahim, N. Diazgranados, J. Franco-Chaves, N. Brutsche, I.D. Henter, and P. Kronstein et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study Neuropsychopharmacology 37 6 2012 1526 1533
13. E.T. Kavalali, and L.M. Monteggia Synaptic mechanisms underlying rapid antidepressant action of ketamine Am. J. Psychiatr. 169 11 2012 1150 1156
14. C.H. Kellner, R.M. Greenberg, J.W. Murrough, E.O. Bryson, M.C. Briggs, and R.M. Pasculli ECT in treatment-resistant depression Am. J. Psychiatr. 169 12 2012 1238 1244
15. S.H. Kennedy, R. Milev, P. Giacobbe, R. Ramasubbu, R.W. Lam, and S.V. Parikh et al. Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies J. Affect. Disord. 117 Suppl. 1 2009 S44 S53
16. S.H. Kennedy, P. Giacobbe, S.J. Rizvi, F.M. Placenza, Y. Nishikawa, and H.S. Mayberg et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years Am. J. Psychiatr. 168 5 2011 502 510
17. A. Kucyi, M.T. Alsuwaidan, S.S. Liauw, and R.S. McIntyre Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder Postgrad. Med. 122 6 2010 107 116
18. S.H. Kennedy, R.W. Lam, S.V. Parikh, S.B. Patten, and A.V. Ravindran Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction J. Affect. Disord. 117 Suppl 1 2009 S1 S2
19. R.C. Kessler, M. Petukhova, N.A. Sampson, A.M. Zaslavsky, and H.U. Wittchen Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States Int. J. Methods. Psychiatr. Res. 21 3 2012 169 184
20. R.C. Kessler, H.S. Akiskal, M. Ames, H. Birnbaum, and P. Greenberg et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers Am. J. Psychiatr. 163 9 2006 1561 1568 (Pubitemid 44465756)
21. D. Khajavi, M. Farokhnia, A. Modabbernia, M. Ashrafi, S.H. Abbasi, and M. Tabrizi et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study J. Clin. Psychiatr. 73 11 2012 1428 1433
22. P.A. Kudlow, D.S. Cha, and R.S. McIntyre Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement Can. J. Psychiatr. 57 12 2012 782 788
23. R.W. Lam, S.H. Kennedy, S. Grigoriadis, R.S. McIntyre, R. Milev, and R. Ramasubbu et al. Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy J. Affect. Disord. 117 Suppl. 1 2009 S26 S43
24. A.M. Lozano, P. Giacobbe, C. Hamani, S.J. Rizvi, S.H. Kennedy, and T.T. Kolivakis et al. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression J. Neurosurg. 116 2 2012 315 322
25. G.S. Malhi, G.B. Parker, J. Crawford, K. Wilhelm, and P.B. Mitchell Treatment-resistant depression: resistant to definition? Acta. Psychiatr. Scand. 112 4 2005 302 309 (Pubitemid 41382737)
26. R.S. McIntyre, and C. O'Donovan The human cost of not achieving full remission in depression Can. J. Psychiatr. 49 3 Suppl. 1 2004 10S 16S (Pubitemid 38506487)
27. J.C. Nelson, and G.I. Papakostas Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials Am. J. Psychiatr. 166 9 2009 980 991
28. G.I. Papakostas, D. Mischoulon, I. Shyu, J.E. Alpert, and M. Fava S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial Am. J. Psychiatr. 167 8 2010 942 948
29. G.I. Papakostas, R.C. Shelton, J.M. Zajecka, B. Etemad, K. Rickels, and A. Clain et al. l-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials Am. J. Psychiatr. 169 12 2012 1267 1274
30. A.A. Patkar, P.S. Masand, C.U. Pae, K. Peindl, C. Hooper-Wood, and P. Mannelli et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression J. Clin. Psychopharmacol. 26 6 2006 653 656 (Pubitemid 44772745)
31. C.L. Raison, R.E. Rutherford, B.J. Woolwine, C. Shuo, P. Schettler, and D.F. Drake et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers JAMA Psychiatr. 70 1 2013 31 41
32. A.V. Ravindran, S.H. Kennedy, M.C. O'donovan, A. Fallu, F. Camacho, and C.E. Binder Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial J. Clin. Psychiatr. 69 1 2008 87 94 (Pubitemid 351282001)
33. S.J. Rizvi, M. Donovan, P. Giacobbe, F. Placenza, S. Rotzinger, and S.H. Kennedy Neurostimulation therapies for treatment resistant depression: a focus on vagus nerve stimulation and deep brain stimulation Int. Rev. Psychiatr. 23 5 2011 424 436
34. H.G. Ruhe, G. van Rooijen, J. Spijker, F.P. Peeters, and A.H. Schene Staging methods for treatment resistant depression. A systematic review J. Affect. Disord. 137 1-3 2012 35 45
35. A.J. Rush, M.H. Trivedi, J.W. Stewart, A.A. Nierenberg, M. Fava, and B.T. Kurian et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study Am. J. Psychiatr. 168 7 2011 689 701
36. G. Salvadore, and J.B. Singh Ketamine as a fast acting antidepressant: current knowledge and open questions CNS. Neurosci. Ther. 6 2013 428 436
37. A.F. Schatzberg, A.J. Rush, B.A. Arnow, P.L. Banks, J.A. Blalock, and F.E. Borian et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not Arch. Gen. Psychiatr. 62 5 2005 513 520 (Pubitemid 40628880)
38. J.K. Soczynska, S.H. Kennedy, H.O. Woldeyohannes, S.S. Liauw, M. Alsuwaidan, and C.Y. Yim et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus Neuromolecular. Med. 13 2 2011 93 116
39. D. Souery, J. Amsterdam, C. de Montigny, Y. Lecrubier, S. Montgomery, and O. Lipp et al. Treatment resistant depression: methodological overview and operational criteria Eur. Neuropsychopharmacol. 1-2 1999 83 91 (Pubitemid 29073687)
40. G.I. Spielmans, M.I. Berman, E. Linardatos, N.Z. Rosenlicht, A. Perry, and A.C. Tsai Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes PLoS Med. 10 3 2013 e1001403
41. Trivedi, M., Culter, A., Richards, C., Lasser, R., Geibel, B., Gao, J., et al., 2013. Efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with major depressive disorder treated with an antidepressant. In: Proceedings of the American Psychiatric Association 164th Annual Meeting. Honolulu, HI.
42. M.H. Trivedi, T.L. Greer, T.S. Church, T.J. Carmody, B.D. Grannemann, and D.I. Galper et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison J. Clin. Psychiatr. 72 5 2011 677 684
43. A. van Randenborgh, J. Huffmeier, D. Victor, K. Klocke, J. Borlinghaus, and M. Pawelzik Contrasting chronic with episodic depression: an analysis of distorted socio-emotional information processing in chronic depression J. Affect. Disord. 141 2-3 2012 177 184
44. N. Wiles, L. Thomas, A. Abel, N. Ridgway, N. Turner, and J. Campbell et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial Lancet 381 9864 2013 375 384